Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma

Dimitrios Makrakis; Rafee Talukder; Genevieve Ihsiu Lin; Leonidas N. Diamantopoulos; Scott Dawsey; Shilpa Gupta; Lucia Carril-Ajuria; Daniel Castellano; Ivan de Kouchkovsky; Vadim S. Koshkin; Joseph J. Park; Ajjai Alva; Mehmet A. Bilen; Tyler F. Stewart; Rana R. McKay; Nishita Tripathi; Neeraj Agarwal; Naomi Vather-Wu; Yousef Zakharia; Rafael Morales-Barrera; Michael E. Devitt; Alessio Cortellini; Claudia Angela Maria Fulgenzi; David J. Pinato; Ariel Nelson; Christopher J. Hoimes; Kavita Gupta; Benjamin A. Gartrell; Alex Sankin; Abhishek Tripathi; Roubini Zakopoulou; Aristotelis Bamias; Jure Murgic; Ana Fröbe; Alejo Rodriguez-Vida; Alexandra Drakaki; Sandy Liu; Eric Lu; Vivek Kumar; Giuseppe Di Lorenzo; Monika Joshi; Pedro Isaacsson-Velho; Lucia Alonso Buznego; Ignacio Duran; Marcus Moses; Albert Jang; Pedro Barata; Guru Sonpavde; Evan Y. Yu; Robert Bruce Montgomery; Petros Grivas; Ali Raza Khaki

doi:10.1016/j.clgc.2022.06.001

Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma

Dimitrios Makrakis, Rafee Talukder, Genevieve Ihsiu Lin, Leonidas N. Diamantopoulos, Scott Dawsey, Shilpa Gupta, Lucia Carril-Ajuria, Daniel Castellano, Ivan de Kouchkovsky, Vadim S. Koshkin, Joseph J. Park, Ajjai Alva, Mehmet A. Bilen, Tyler F. Stewart, Rana R. McKay, Nishita Tripathi, Neeraj Agarwal, Naomi Vather-Wu, Yousef Zakharia, Rafael Morales-BarreraMichael E. Devitt, Alessio Cortellini, Claudia Angela Maria Fulgenzi, David J. Pinato, Ariel Nelson, Christopher J. Hoimes, Kavita Gupta, Benjamin A. Gartrell, Alex Sankin, Abhishek Tripathi, Roubini Zakopoulou, Aristotelis Bamias, Jure Murgic, Ana Fröbe, Alejo Rodriguez-Vida, Alexandra Drakaki, Sandy Liu, Eric Lu, Vivek Kumar, Giuseppe Di Lorenzo, Monika Joshi, Pedro Isaacsson-Velho, Lucia Alonso Buznego, Ignacio Duran, Marcus Moses, Albert Jang, Pedro Barata, Guru Sonpavde, Evan Y. Yu, Robert Bruce Montgomery, Petros Grivas, Ali Raza Khaki

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

Background: Sites of metastasis have prognostic significance in advanced urothelial carcinoma (aUC), but more information is needed regarding outcomes based on metastatic sites in patients treated with immune checkpoint inhibitors (ICI). We hypothesized that presence of liver/bone metastases would be associated with worse outcomes with ICI. Methods: We identified a retrospective cohort of patients with aUC across 26 institutions, collecting demographics, clinicopathological, treatment, and outcomes information. Outcomes were compared with logistic (observed response rate; ORR) and Cox (progression-free survival; PFS, overall survival; OS) regression between patients with/without metastasis beyond lymph nodes (LN) and those with/without bone/liver/lung metastasis. Analysis was stratified by 1st or 2nd⁺ line. Results: We identified 917 ICI-treated patients: in the 1st line, bone/liver metastases were associated with shorter PFS (Hazard ratio; HR: 1.65 and 2.54), OS (HR: 1.60 and 2.35, respectively) and lower ORR (OR: 0.48 and 0.31). In the 2nd⁺ line, bone/liver metastases were associated with shorter PFS (HR: 1.71 and 1.62), OS (HR: 1.76 and 1.56) and, for bone-only metastases, lower ORR (OR: 0.29). In the 1st line, LN-confined metastasis was associated with longer PFS (HR: 0.53), OS (HR:0.49) and higher ORR (OR: 2.97). In the 2nd⁺ line, LN-confined metastasis was associated with longer PFS (HR: 0.47), OS (HR: 0.54), and higher ORR (OR: 2.79); all associations were significant. Conclusion: Bone and/or liver metastases were associated with worse, while LN-confined metastases were associated with better outcomes in patients with aUC receiving ICI. These findings in a large population treated outside clinical trials corroborate data from trial subset analyses.

Original language	English (US)
Pages (from-to)	e440-e452
Journal	Clinical Genitourinary Cancer
Volume	20
Issue number	5
DOIs	https://doi.org/10.1016/j.clgc.2022.06.001
State	Published - Oct 2022

All Science Journal Classification (ASJC) codes

Oncology
Urology

Access to Document

10.1016/j.clgc.2022.06.001

Cite this

Makrakis, D., Talukder, R., Lin, G. I., Diamantopoulos, L. N., Dawsey, S., Gupta, S., Carril-Ajuria, L., Castellano, D., de Kouchkovsky, I., Koshkin, V. S., Park, J. J., Alva, A., Bilen, M. A., Stewart, T. F., McKay, R. R., Tripathi, N., Agarwal, N., Vather-Wu, N., Zakharia, Y., ... Khaki, A. R. (2022). Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 20(5), e440-e452. https://doi.org/10.1016/j.clgc.2022.06.001

@article{4c2c0f7bc8f44471b8eb99a592b29e3b,

title = "Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma",

abstract = "Background: Sites of metastasis have prognostic significance in advanced urothelial carcinoma (aUC), but more information is needed regarding outcomes based on metastatic sites in patients treated with immune checkpoint inhibitors (ICI). We hypothesized that presence of liver/bone metastases would be associated with worse outcomes with ICI. Methods: We identified a retrospective cohort of patients with aUC across 26 institutions, collecting demographics, clinicopathological, treatment, and outcomes information. Outcomes were compared with logistic (observed response rate; ORR) and Cox (progression-free survival; PFS, overall survival; OS) regression between patients with/without metastasis beyond lymph nodes (LN) and those with/without bone/liver/lung metastasis. Analysis was stratified by 1st or 2nd+ line. Results: We identified 917 ICI-treated patients: in the 1st line, bone/liver metastases were associated with shorter PFS (Hazard ratio; HR: 1.65 and 2.54), OS (HR: 1.60 and 2.35, respectively) and lower ORR (OR: 0.48 and 0.31). In the 2nd+ line, bone/liver metastases were associated with shorter PFS (HR: 1.71 and 1.62), OS (HR: 1.76 and 1.56) and, for bone-only metastases, lower ORR (OR: 0.29). In the 1st line, LN-confined metastasis was associated with longer PFS (HR: 0.53), OS (HR:0.49) and higher ORR (OR: 2.97). In the 2nd+ line, LN-confined metastasis was associated with longer PFS (HR: 0.47), OS (HR: 0.54), and higher ORR (OR: 2.79); all associations were significant. Conclusion: Bone and/or liver metastases were associated with worse, while LN-confined metastases were associated with better outcomes in patients with aUC receiving ICI. These findings in a large population treated outside clinical trials corroborate data from trial subset analyses.",

author = "Dimitrios Makrakis and Rafee Talukder and Lin, {Genevieve Ihsiu} and Diamantopoulos, {Leonidas N.} and Scott Dawsey and Shilpa Gupta and Lucia Carril-Ajuria and Daniel Castellano and {de Kouchkovsky}, Ivan and Koshkin, {Vadim S.} and Park, {Joseph J.} and Ajjai Alva and Bilen, {Mehmet A.} and Stewart, {Tyler F.} and McKay, {Rana R.} and Nishita Tripathi and Neeraj Agarwal and Naomi Vather-Wu and Yousef Zakharia and Rafael Morales-Barrera and Devitt, {Michael E.} and Alessio Cortellini and Fulgenzi, {Claudia Angela Maria} and Pinato, {David J.} and Ariel Nelson and Hoimes, {Christopher J.} and Kavita Gupta and Gartrell, {Benjamin A.} and Alex Sankin and Abhishek Tripathi and Roubini Zakopoulou and Aristotelis Bamias and Jure Murgic and Ana Fr{\"o}be and Alejo Rodriguez-Vida and Alexandra Drakaki and Sandy Liu and Eric Lu and Vivek Kumar and Lorenzo, {Giuseppe Di} and Monika Joshi and Pedro Isaacsson-Velho and Buznego, {Lucia Alonso} and Ignacio Duran and Marcus Moses and Albert Jang and Pedro Barata and Guru Sonpavde and Yu, {Evan Y.} and Montgomery, {Robert Bruce} and Petros Grivas and Khaki, {Ali Raza}",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",

year = "2022",

month = oct,

doi = "10.1016/j.clgc.2022.06.001",

language = "English (US)",

volume = "20",

pages = "e440--e452",

journal = "Clinical Genitourinary Cancer",

issn = "1558-7673",

publisher = "Elsevier Inc.",

number = "5",

}

Makrakis, D, Talukder, R, Lin, GI, Diamantopoulos, LN, Dawsey, S, Gupta, S, Carril-Ajuria, L, Castellano, D, de Kouchkovsky, I, Koshkin, VS, Park, JJ, Alva, A, Bilen, MA, Stewart, TF, McKay, RR, Tripathi, N, Agarwal, N, Vather-Wu, N, Zakharia, Y, Morales-Barrera, R, Devitt, ME, Cortellini, A, Fulgenzi, CAM, Pinato, DJ, Nelson, A, Hoimes, CJ, Gupta, K, Gartrell, BA, Sankin, A, Tripathi, A, Zakopoulou, R, Bamias, A, Murgic, J, Fröbe, A, Rodriguez-Vida, A, Drakaki, A, Liu, S, Lu, E, Kumar, V, Lorenzo, GD, Joshi, M, Isaacsson-Velho, P, Buznego, LA, Duran, I, Moses, M, Jang, A, Barata, P, Sonpavde, G, Yu, EY, Montgomery, RB, Grivas, P & Khaki, AR 2022, 'Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma', Clinical Genitourinary Cancer, vol. 20, no. 5, pp. e440-e452. https://doi.org/10.1016/j.clgc.2022.06.001

TY - JOUR

T1 - Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma

AU - Makrakis, Dimitrios

AU - Talukder, Rafee

AU - Lin, Genevieve Ihsiu

AU - Diamantopoulos, Leonidas N.

AU - Dawsey, Scott

AU - Gupta, Shilpa

AU - Carril-Ajuria, Lucia

AU - Castellano, Daniel

AU - de Kouchkovsky, Ivan

AU - Koshkin, Vadim S.

AU - Park, Joseph J.

AU - Alva, Ajjai

AU - Bilen, Mehmet A.

AU - Stewart, Tyler F.

AU - McKay, Rana R.

AU - Tripathi, Nishita

AU - Agarwal, Neeraj

AU - Vather-Wu, Naomi

AU - Zakharia, Yousef

AU - Morales-Barrera, Rafael

AU - Devitt, Michael E.

AU - Cortellini, Alessio

AU - Fulgenzi, Claudia Angela Maria

AU - Pinato, David J.

AU - Nelson, Ariel

AU - Hoimes, Christopher J.

AU - Gupta, Kavita

AU - Gartrell, Benjamin A.

AU - Sankin, Alex

AU - Tripathi, Abhishek

AU - Zakopoulou, Roubini

AU - Bamias, Aristotelis

AU - Murgic, Jure

AU - Fröbe, Ana

AU - Rodriguez-Vida, Alejo

AU - Drakaki, Alexandra

AU - Liu, Sandy

AU - Lu, Eric

AU - Kumar, Vivek

AU - Lorenzo, Giuseppe Di

AU - Joshi, Monika

AU - Isaacsson-Velho, Pedro

AU - Buznego, Lucia Alonso

AU - Duran, Ignacio

AU - Moses, Marcus

AU - Jang, Albert

AU - Barata, Pedro

AU - Sonpavde, Guru

AU - Yu, Evan Y.

AU - Montgomery, Robert Bruce

AU - Grivas, Petros

AU - Khaki, Ali Raza

PY - 2022/10

Y1 - 2022/10

N2 - Background: Sites of metastasis have prognostic significance in advanced urothelial carcinoma (aUC), but more information is needed regarding outcomes based on metastatic sites in patients treated with immune checkpoint inhibitors (ICI). We hypothesized that presence of liver/bone metastases would be associated with worse outcomes with ICI. Methods: We identified a retrospective cohort of patients with aUC across 26 institutions, collecting demographics, clinicopathological, treatment, and outcomes information. Outcomes were compared with logistic (observed response rate; ORR) and Cox (progression-free survival; PFS, overall survival; OS) regression between patients with/without metastasis beyond lymph nodes (LN) and those with/without bone/liver/lung metastasis. Analysis was stratified by 1st or 2nd+ line. Results: We identified 917 ICI-treated patients: in the 1st line, bone/liver metastases were associated with shorter PFS (Hazard ratio; HR: 1.65 and 2.54), OS (HR: 1.60 and 2.35, respectively) and lower ORR (OR: 0.48 and 0.31). In the 2nd+ line, bone/liver metastases were associated with shorter PFS (HR: 1.71 and 1.62), OS (HR: 1.76 and 1.56) and, for bone-only metastases, lower ORR (OR: 0.29). In the 1st line, LN-confined metastasis was associated with longer PFS (HR: 0.53), OS (HR:0.49) and higher ORR (OR: 2.97). In the 2nd+ line, LN-confined metastasis was associated with longer PFS (HR: 0.47), OS (HR: 0.54), and higher ORR (OR: 2.79); all associations were significant. Conclusion: Bone and/or liver metastases were associated with worse, while LN-confined metastases were associated with better outcomes in patients with aUC receiving ICI. These findings in a large population treated outside clinical trials corroborate data from trial subset analyses.

AB - Background: Sites of metastasis have prognostic significance in advanced urothelial carcinoma (aUC), but more information is needed regarding outcomes based on metastatic sites in patients treated with immune checkpoint inhibitors (ICI). We hypothesized that presence of liver/bone metastases would be associated with worse outcomes with ICI. Methods: We identified a retrospective cohort of patients with aUC across 26 institutions, collecting demographics, clinicopathological, treatment, and outcomes information. Outcomes were compared with logistic (observed response rate; ORR) and Cox (progression-free survival; PFS, overall survival; OS) regression between patients with/without metastasis beyond lymph nodes (LN) and those with/without bone/liver/lung metastasis. Analysis was stratified by 1st or 2nd+ line. Results: We identified 917 ICI-treated patients: in the 1st line, bone/liver metastases were associated with shorter PFS (Hazard ratio; HR: 1.65 and 2.54), OS (HR: 1.60 and 2.35, respectively) and lower ORR (OR: 0.48 and 0.31). In the 2nd+ line, bone/liver metastases were associated with shorter PFS (HR: 1.71 and 1.62), OS (HR: 1.76 and 1.56) and, for bone-only metastases, lower ORR (OR: 0.29). In the 1st line, LN-confined metastasis was associated with longer PFS (HR: 0.53), OS (HR:0.49) and higher ORR (OR: 2.97). In the 2nd+ line, LN-confined metastasis was associated with longer PFS (HR: 0.47), OS (HR: 0.54), and higher ORR (OR: 2.79); all associations were significant. Conclusion: Bone and/or liver metastases were associated with worse, while LN-confined metastases were associated with better outcomes in patients with aUC receiving ICI. These findings in a large population treated outside clinical trials corroborate data from trial subset analyses.

UR - http://www.scopus.com/inward/record.url?scp=85133310824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85133310824&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2022.06.001

DO - 10.1016/j.clgc.2022.06.001

M3 - Article

C2 - 35778337

AN - SCOPUS:85133310824

SN - 1558-7673

VL - 20

SP - e440-e452

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

IS - 5

ER -

Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this